 Bragar Eagel Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Cellular Biomedicine Group, Inc. NASDAQ: CBMG breached their fiduciary duties or violated the federal securities laws in connection with the companys acquisition by a consortium led by Cellular Biomedicines CEO Bizuo Liu the Consortium. 